Why the study?
Recent research advances have continuously updated diagnostic and therapeutic strategies for pulmonary arterial hypertension associated with adult congenital heart disease, requiring updated guidance to standardize clinical management in China.
Provides updated, evidence-based clinical practice guidelines for diagnosing and treating pulmonary arterial hypertension associated with adult congenital heart disease in China.
Answers are grounded in this paper and cite their sources.
Standardizes PAH diagnosis and treatment in adult CHD across China; extends global evidence with localized national guidelines.
Congenital heart disease is a common cause of pulmonary hypertension. In recent years, with advances in research in the field of pulmonary arterial hypertension associated with adult congenital heart disease, diagnostic and therapeutic strategies have been continuously updated. To guide clinical diagnosis and treatment, the Chinese Society of Cardiology, Chinese Medical Association; Chinese College of Cardiovascular Physicians; and the Editorial Board of Chinese Journal of Cardiology have organized relevant experts to formulate this guideline based on the latest domestic and international clinical research findings, especially evidence-based medical findings from the Chinese population. The guideline aims to further standardize the clinical diagnosis and treatment of pulmonary arterial hypertension associated with adult congenital heart disease in China.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied Pulmonary arterial hypertension associated with adult congenital heart disease. The 2026 CSC/CCCP guidelines standardize the clinical diagnosis and treatment of pulmonary arterial hypertension associated with adult congenital heart disease in China.
Synapse has enriched 10 related papers. Consider them for comparative context: